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Abstract
Background: Coronary artery disease (CAD) is the leading cause of mortality worldwide. Identifying 
key pathogenic genes  benefits  the understanding  molecular mechanism of CAD.
Methods: In this study, 5 microarray data sets from the blood sample of 312 CADs and 277 healthy 
controls were downloaded. Limma and metaMA packages were used to identify differentially expressed 
genes. The functional enrichment analysis of differentially expressed genes was further performed by 
Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. Additionally, protein–protein interac-
tion and transcript factors-target networks were performed based on top 10 up- and down-regulated 
differentially expressed genes to further study the biological function. Last, real-time quantitative poly-
merase chain reaction (RT-qPCR) was used to validate the integrated analysis result. 
Results: A total of 528 differentially expressed genes were obtained. All differentially expressed genes 
were significantly involved in signal transduction and the MAPK signaling pathway. Among MAPK 
signaling pathway, IL1R2, ARRB2 and PRKX were associated with CAD. Furthermore, there were 
4 common differentially expressed genes including PLAUR, HSPH1, ZMYND11 and S100A8 in the 
protein–protein interaction and transcript factors-target networks, which played crucial roles in the 
development of CAD. In quantitative RT-qPCR, the expression of PRKX, HSPH1 and ZMYND11 was 
down-regulated and consistent with the integrated analysis. 
Conclusions: Identified 7 differentially expressed genes (IL1R2, ARRB2, PRKX, PLAUR, HSPH1, 
ZMYND11 and S100A8) may play crucial roles in the development of CAD. (Cardiol J 2018; 25, 3: 403–411)
Key words: coronary artery disease, differentially expressed gene, protein–protein  
interaction, transcript factors
Introduction
Coronary artery disease (CAD) is a heart 
disease with atherosclerosis lesion and leads to 
vessel blockage, myocardial ischemia, hypoxia and 
necrosis. It is a major health problem all over the 
world and is supposed to be the primary cause of 
death by 2020 [1, 2]. Atherosclerosis is the main 
cause of CAD and the process begins early in 
a progressive interaction between genetic factors 
and the environment [3]. The metabolic syndrome, 
also present in CAD, is defined as a number of risk 
factors including obesity, hypertension, dyslipi-
demia and hyperglycemia [3]. Additionally, some 
risk factors such as age, sex and smoking are linked 
to CAD [4].
Up to now, with advances in both percutaneous 
coronary intervention and coronary artery bypass 
graft surgery, mortality from CAD has remarkably 
decreased [5]. However, the poor prognosis for pa-
tients with CAD and unclear pathology mechanism 
of CAD is still a hot topic. Therefore, identifying key 
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genes in patients with CAD could facilitate a better 
understanding of the important role in the process 
of CAD, which will further help provide the potential 
molecular mechanism in the development of CAD.
Using the microarray data analysis, Yang 
et al. [6] identified the biomarkers for ischemic 
cardiomyopathy. It is noted that high throughput 
sequencing is a fast and comprehensive method 
of studying various diseases. In this study, the 
transcription data of CAD was integrated and ana-
lyzed identifying 528 differentially expressed genes 
(DEGs) including 310 up-regulated and 218 down-
regulated genes. Gene Ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) 
were further used to annotate function of identi-
fied DEGs. In order to further study the regulatory 
roles of DEGs, protein–protein interaction (PPI) 
and transcript factors (TFs)-target networks were 
performed. At last, 7 key DEGs (IL1R2, ARRB2, 
PRKX, PLAUR, HSPH1, ZMYND11 and S100A8) 
and MAPK signaling pathways were identified, 
which may play vital roles in the process of CAD. 
Methods
Microarray data
In this study, the keywords were used: (“coro-
nary disease” [MeSH Terms] OR coronary disease 
[All Fields]) AND “Homo sapiens” [porn] AND 
“gse” [Filter] AND “Expression profiling by array” 
[Filter]. Then, five microarray data sets including 
GSE71226, GSE42148, GSE20681, GSE20680 
and GSE12288 were downloaded from the GEO 
database (http://www.ncbi.nlm.nih.gov/geo/). And, 
all selected datasets were transcription data of the 
blood samples (no drug stimulation or transfected 
treatment) from 312 CAD and 277 healthy controls. 
The control groups of these databases were prop-
erly matched. Additionally, age and sex between 
case and normal groups were properly matched. 
There were no comorbidities in both case and nor-
mal groups. Detailed information of five microarray 
data sets is listed in Table 1.
Differentially expressed genes identification 
and functional enrichment analysis
The data was first preprocessed by remov-
ing the probes that corresponded to multiple 
genes. Among genes with multiple corresponding 
probes, only those genes with the highest average 
expression were reserved. Then, 20468 genes 
in GSE71226, 19726 genes in GSE42148, 19751 
genes in GSE20681, 19751 genes in GSE20680 
and 19751 genes in GSE12288 were obtained and 
12013 genes were identified by intersected above 
reserved genes. Limma and metaMA packages 
were further applied to identify DEGs and an 
inverse normal method was used to combine the 
p value [7]. Finally, candidate DEGs were chosen 
with a cut-off p value of < 0.05. In order to study 
the biological characteristics of the DEGs, enrich-
ment analysis was conducted by GeneCoDis. All 
DEGs were annotated and built on the GO (http://
geneontology.org/) and the KEGG [8] dataset.
Protein–protein interaction network analysis
It is a known fact that proteins and other mol-
ecules were not playing roles alonebut interact with 
each other and form a network, which determines 
the characteristic of cells, tissue and individuals. It 
may result in dysfunction of the cell upon this net-
work and is thus destroyed. In order to explore the 
molecular mechanism of CAD, PPI was performed 
based on the dataset of BioGRID [9] and the network 
was constructed using Cytoscape [10]. Selected 
genes that had a large number of interactions with 
other genes were considered to have more important 
roles in the pathogenesis. And the degree of a gene 
Table 1. Five microarray data sets.
GEO accession Author Platform Samples (P:N) Year
GSE71226 Meng F GPL570[HG-U133_Plus_2] Affymetrix Human  
Genome U133 Plus 2.0 Array
3:3 2015
GSE42148 Arvind P GPL13607 Agilent-028004 SurePrint G3 Human GE 
8x60K Microarray (Feature Number version)
13:11 2012
GSE20681 Biros E GPL4133Agilent-014850 Whole Human Genome  
Microarray 4x44K G4112F (Feature Number version)
99:99 2011
GSE20680 Wingrove JA GPL4133Agilent-014850 Whole Human Genome  
Microarray 4x44K G4112F (Feature Number version)
87:52 2011
GSE12288 Grass P GPL96 [HG-U133A] Affymetrix Human Genome 
U133A Array
110:112 2009
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was the number of the exhibited interactions. Gene 
with a degree of > 10 was considered as a critical 
hub molecule.
Transcript factors screening of DEGs
Transcript factors can regulate the expression 
of various genes by binding to the specific DNA 
sequence in the promoter of target genes. In order 
to further study the molecular mechanism of CAD, 
the upstream promoter 2KB sequence of top 10 up- 
and down-regulated DEGs was first downloaded 
from the UCSC website. Then, the tool of match 
in the TRANSFAC website was used to identify 
the TFs. Last, the regulation network between 
TFs and DEGs was established through Cytoscape 
software. Selected genes that had a large number 
of interactions with TFs were considered to play 
more significant roles in the pathogenesis. And 
the gene degree was the number of the exhibited 
interactions. A gene with a degree of > 5 was 
considered as a critical hub molecule.
RT-qPCR
Five patients diagnosed as CAD and 5 health 
controls were enrolled in this study. Both the 
CAD and corresponding normal blood samples 
were obtained and immediately frozen in liquid 
nitrogen. Written informed consent was given by 
CAD patients before enrollment and this study 
was approved by the ethics committee of the local 
hospital.
According to manufacturer protocols, total 
RNA of the blood samples was extracted using the 
RNAliquid Reagent (Beijing Huitian east technol-
ogy co., LTD). And the A260/280 ratio was 1.8–2.0, 
which indicated the purity of RNA extracted. 1 µg 
RNA was applied to synthesize DNA by FastQuant 
cDNA Reverse Transcriptase (TIANGEN). Then 
real-time polymerase chain reaction (PCR) was 
performed in an ABI 7500 real-time PCR system 
with SuperReal PreMix Plus (SYBR Green) Su-
perReal Mix (TIANGEN). All reactions were per-
formed in triplicate and GAPDH was considered as 
a negative control. Comparative gene expressions 
were analyzed by the log2 (fold change) method. 
Results
Differentially expressed genes selection 
and functional analysis 
In this study, a total of 528 DEGs were identi-
fied. Among which, 310 and 218 genes were up-
regulated and down-regulated, respectively. The 
top ten up-regulated genes were LIN7A, MMP9, 
MYBPH, MBOAT2, ITPK1, CEACAM4, PLAUR, 
USB1, CBS and S100A8. And NBEA, ZMYND11, 
BYSL, DCXR, PRKX, HLA-DPB1, HSPH1, SCRIB, 
LAGE3 and CROCCP2 were the top 10 down-regu-
lated genes. After cluster analysis, the heat map of 
top 100 DEGs was presented in Supplementary 
Figure 1 and the top 100 genes were listed in 
Supplementary Table 1. The GO analysis showed 
that these DEGs were significantly enriched in 
signal transduction, cell adhesion, positive regu-
lation of apoptosis process of biological process 
term and protein binding, hydrolase activity, nu-
cleotide binding of molecular function term and 
cytoplasm, plasma membrane, nucleus of cellular 
component term. Additionally, these DEGs were 
remarkably involved in leishmaniasis, leukocyte 
transendothelial migration, phagosome, amoebiasis 
and MAPK signal pathway. The GO and KEGG 
annotation function were shown in Tables 2 and 3, 
respectively. It is pointed out that there were 
13 DEGs (MAP4K2, IL1R2, RASGRP1, DDIT3, 
FAS, CACNA1H, ARRB2, HSPA6, PAK1, PRKX, 
MKNK1, MAPK14 and HSPB1) participating in 
the MAPK signaling pathway. The MAPK signaling 
pathway is shown in Figure 1.
Protein–protein interaction network analysis
Protein–protein interaction is crucial to all 
biological processes [11]. In order to study the bio-
logical mechanism of CAD, the PPI involving top 10 
(up- and down-regulated) DEGs were established 
(Suppl. Fig. 2). This network was comprised of 
node and edge. The node and edge represented 
the protein and the interaction, respectively. In 
the network, there were 653 nodes and 688 edges. 
There were 10 up-regulated and 9 down-regulated 
DEGs in the network. Among which, the top 8 
DEGs with the highest degree were BYSL (degree 
= 118), PLAUR (degree = 98), HSPH1 (degree 
= 84), CBS (degree = 64), ZMYND11 (degree = 51), 
LAGE3 (degree = 45), S100A8 (degree = 43) and 
SCRIB (degree = 43). 
Transcript factors regulatory network
Transcript factors play roles in regulating 
numbers of genes, such as cytokines, growth 
factors, cell adhesion molecules and so on. The 
study of TFs-target genes network is valuable 
in understanding the regulatory mechanism of 
biological function. In order to further study the 
biological roles of top 10 DEGs (up- and down-
regulated) under the regulation of TFs, TFs-target 
genes regulatory network was performed (Fig. 2). 
The network was comprised of 60 nodes and 115 
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edges. A total of 378 interaction pairs were obtained 
involving 40 TFs. The top 6 TFs that covered the 
most downstream genes were Oct-1, Evi-1, Pax-4, 
AP-1, FOXD3 and HNF-3beta. Among which, Oct-1 
(degree = 11), Pax-4 (degree = 8) and Evi-1 (de-
gree = 8) were the TFs with the highest degree. 
At the same time, the top 8 target DEGs with 
the highest degree were HSPH1 (degree = 12), 
ZMYND11 (degree = 10), S100A8 (degree = 9), 
PRKX (degree = 9), PLAUR (degree = 9), LIN7A 
(degree = 8), CEACAM4 (degree = 8), DCXR 
(degree = 7). 
RT-qPCR
Previous study validated the expression of 
some microRNAs by quantitative polymerase chain 
reaction in plasma for stable LAD [12]. In this 
study, 5 patients of CAD and 5 health controls were 
enrolled in this study for validation. The collected 
blood samples were used to validate the expression 
Table 2. The enriched Gene Ontology (GO) annotation of differentially expressed genes in coronary 
artery disease.
GO ID GO term Support FDR
Biological process
GO:0007165 Signal transduction 54 3.37E-10
GO:0007155 Cell adhesion 33 1.47E-08
GO:0043065 Positive regulation of apoptotic process 14 0.000183
GO:0006954 Inflammatory response 17 0.000197
GO:0042493 Response to drug 18 0.000211
GO:0014070 Response to organic cyclic compound 11 0.000232
GO:0007596 Blood coagulation 22 0.000352
GO:0006508 Proteolysis 24 0.000462
GO:0019047 Provirus integration 4 0.000544
GO:0006955 Immune response 19 0.000792
Molecular function
GO:0005515 Protein binding 166 2.50E-28
GO:0016787 Hydrolase activity 50 7.03E-12
GO:0000166 Nucleotide binding 78 1.71E-11
GO:0046872 Metal ion binding 87 1.60E-08
GO:0005524 ATP binding 54 1.64E-07
GO:0003824 Catalytic activity 23 9.48E-07
GO:0004872 Receptor activity 49 5.96E-05
GO:0005488 Binding 28 0.000389
GO:0042803 Protein homodimerization activity 22 0.000651
GO:0005529 Sugar binding 12 0.000732
GO:0003700 Sequence-specific DNA binding transcription factor activity 31 0.000779
Cellular component
GO:0005737 Cytoplasm 177 3.33E-25
GO:0005886 Plasma membrane 126 1.19E-18
GO:0005634 Nucleus 157 8.86E-16
GO:0016020 Membrane 128 2.96E-15
GO:0005624 Membrane fraction 37 3.23E-13
GO:0009986 Cell surface 27 3.84E-12
GO:0005887 Integral to plasma membrane 49 2.00E-11
GO:0005829 Cytosol 77 2.11E-11
GO:0016021 Integral to membrane 121 1.69E-10
GO:0005739 Mitochondrion 57 1.70E-10
FDR — false discovery rate
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of integrated analysis. PRKX, HSPH1, ZMYND11 
and MMP9 were randomly selected. The real-time 
quantitative polymerase chain reaction (RT-qPCR) 
results showed that PRKX, HSPH1 and ZMYND11 
were down-regulated, which obtained consistent 
data with integrated analysis. While MMP9 was 
down-regulated, which were not in accordance with 
the integrated analysis result. The consequence is 
shown in Figure 3.
Discussion
Coronary artery disease is the leading killer 
and accounts for one-third of all patient deaths 
in the world [13]. It is noted that gene expres-
sion profiling is an important way to investigate 
the underlying pathology of CAD. In the present 
study, integration analysis of transcription data in 
CAD was performed. Five microarray data sets 
were downloaded from the GEO dataset. GO and 
KEGG annotation analysis was further used to 
investigate the biological function of these DEGs. 
Additionally, PPI interaction network and TFs-
target genes analysis were utilized to explore 
the underlying regulatory mechanism of DEGs in 
CAD. Finally, RT-qPCR was used to validate the 
integrated analysis.
In KEGG functional annotation analysis, it 
was found that there were 13 DEGs, such as 
IL1R2, ARRB2 and PRKX involved in the MAPK 
signaling pathway. MAPK is serine/threonine 
kinase, which is activated in response to various 
signals. Furthermore, MAPK is associated with 
a large number of biological processes including 
cell proliferation, cell apoptosis, cell transformation 
and vast cell signaling pathways [14]. Interleukin 1 
receptor type 2 (IL1R2) is an anti-inflammatory 
gene [15]. It is pointed out that the expression of 
IL1R2 is remarkably up-regulated in ST-segment 
elevation myocardial infarction [16]. It is also up-
regulated in peripheral blood mononuclear cells and 
whole blood in patients with advanced heart failure 
[17]. Additionally, it is involved in the p38 MAPK 
signaling pathway in patients with cardioembolic 
and large vessel atherosclerotic stroke [18]. It is 
worth mentioning that IL1R2 is found to be related 
to CAD [19]. Thus it can be seen that IL1R2 plays 
an important role in heart development. In this 
study,  it wasfound that IL1R2 was up-regulated 
in CAD and participated in the MAPK signaling 
Table 3. The enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation of differentially 
expressed genes in coronary artery disease.
KEGG ID KEGG term Support FDR Gene list
hsa05140 Leishmaniasis 9 9.69E-05 TLR2, NCF1, ITGAM, TLR4, HLA-DPB1, FCGR2A, 
MAPK14, NCF4, NCF2
hsa04670 Leukocyte transen-
dothelial migration
10 0.000426 MMP9, CTNNA1, NCF1, CD99, ITGAM, RHOH, VASP, 
MAPK14, NCF4, NCF2
hsa04145 Phagosome 11 0.000577 CTSS, TLR2, NCF1, ITGAM, TLR4, HLA-DPB1, 
FCGR2A, NCF4, NCF2, ATP6V1B2, PLA2R1
hsa05146 Amoebiasis 9 0.000625 TLR2, IL1R2, ITGAM, CXCL1, TLR4, ARG1, PRKX, 
HSPB1, SERPINB4
hsa04380 Osteoclast  
differentiation
10 0.000669 NCF1, SIRPA, SIRPB1, LILRB3, FCGR2A, LILRA2, SPI1, 
MAPK14, NCF4, NCF2
hsa00910 Nitrogen  
metabolism
5 0.000826 HAL, CA5A, GLUL, CA5B, CA4
hsa04060 Cytokine-cytokine 
receptor interaction
14 0.000908 INHBB, TNFRSF10C, IL11, IL1R2, FAS, CXCL1, EDA,  
FLT3, HGF, TNFRSF9, FLT3LG, ACVR2A, CD27, CCR3
hsa05152 Tuberculosis 11 0.001210 CTSS, TLR2, ITGAM, TLR4, HLA-DPB1, FCGR2A, 
MAPK14, HSPD1, TLR1, LSP1, PLA2R1
hsa04110 Cell cycle 9 0.0018249 MDM2, CDC7, MCM7, CCND2, CDK4, CDKN2B, 
TFDP1, MCM3, CDKN2D
hsa05162 Measles 9 0.002509 TNFRSF10C, TLR2, CCND2, CDK4, STAT3, FAS, TLR4, 
HSPA6, PRKCQ
hsa04010 MAPK signaling 
pathway
13 0.002564 MAP4K2, IL1R2, RASGRP1, DDIT3, FAS, CACNA1H, 
ARRB2, HSPA6, PAK1, PRKX, MKNK1, MAPK14, 
HSPB1
FDR — false discovery rate
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pathway. This further demonstrated the relation-
ship between IL1R2 and CAD, which indicated 
that IL1R2 may function by the MAPK signaling 
pathway in CAD. 
The protein encoded by arrestin beta 2 
(ARRB2) belongs to the arrestin/beta-arrestin 
protein family [20]. It is the most obviously altered 
gene in chronic thromboembolic pulmonary hyper-
tension [21]. It was found that ARRB2 is involved 
in the inflammation system of the MAPK signaling 
pathway in patients with atrial fibrillation [22]. 
Additionally, it was reported that ARRB2 is a hub 
gene with a degree of > 10 in the PPI network in 
CAD [20]. In the present study, it was found that 
the expression of ARRB2 was increased in CAD 
and significantly enriched in the signaling pathway 
of MAPK. This suggested that ARRB2 may play 
crucial roles in the process of CAD.
The human protein kinase, X-linked (PRKX) 
is a member of the family of cAMP-dependent 
serine threonine kinases. It has been noted that 
PRKX is enriched in the MAPK signaling pathway 
in patients with atrial fibrillation [23]. In this study, 
it was found that the expression of PRKX was 
down-regulated in CAD and RT-qPCR validated 
this expression. In addition, PRKX remarkably 
participated in the signaling pathway of MAPK and 
was also a downstream gene in a higher degree in 
the network of TFs-target gene in CAD. This sug-
gested that PRKX may play an important regula-
tory role in the development of CAD. 
In the PPI network and TFs-target regulatory 
network, we found 4 common hub DEGs including 
PLAUR, HSPH1, ZMYND11 and S100A8, all of which 
were top 10 DEGs and played a vital role in CAD. 
Plasminogen activator, urokinase receptor (PLAUR) 
Figure 1. The significantly enriched Kyoto Encyclopedia of Genes and Genomes pathway of differentially expressed genes 
in coronary artery disease. Color diamonds represent the differentially expressed genes in coronary artery disease.
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In addition, the up-regulated expression of PLAUR 
has been implicated in vascular homeostasis and 
pathology of peripheral arterial disease [26, 27]. In-
terestingly, PLAUR is a crucial atherogenic gene and 
is considered the marker of unstable human atheroma 
[28, 29]. Furthermore, it expresses in patients with 
CAD and is regarded a therapeutic target for CAD [30, 
31]. In this study, increased expression of PLAUR in 
CAD was found, which further demonstrated the role 
of PLAUR in the process of CAD.
Heat shock protein family H (HSPH) member 1 
(HSPH1) is a cardiac age-dependent protein 
[32]. In this study, the expression of HSPH1 was 
decreased in CAD and RT-qPCR also consistent 
with the integrated analysis. Additionally, HSPH1 
was involved in the PPI and TFs-target network, 
which suggested the role of HSPH1 in CAD. Zinc 
finger MYND-type containing 11 (ZMYND11) is 
a candidate tumor suppressor and expresses in 
diverse tissues [33, 34]. It is found that ZMYND11 
plays critical roles in repressing tumor cell tran-
scriptional process and the low expression level of 
ZMYND11 in patients with breast cancer is associ-
ated with worse prognosis [35, 36]. In the present 
Figure 2. Transcript factors-target genes regulatory network in coronary artery disease. Rhombus and ellipses rep-
resent the genes and transcript factors, respectively. The red and green colors represent up-regulation and down-
regulation, respectively. The gray line indicates the interaction between gene and transcript factors.
Figure 3. Relative expression levels of PRKX, MMP9, 
HSPH1, and ZMYND11 at the validation stage in patients 
with coronary artery disease (n = 5) and controls (n = 5). 
The expression level was presented as 2–DDct; *p < 0.05; 
**p < 0.01.
is a platelet-related angiogenesis gene associated 
with left ventricular function [24]. It is found differ-
entially expressed in acute myocardial infarction [25]. 
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study, we found the down-regulated expression 
of ZMYND11 and RT-qPCR also validated the 
expression. This indicated that ZMYND11 may be 
involved in CAD.
S100 calcium binding protein A8 (S100A8) 
and S100A9 can form homodimers (S100A8/
A9) and have manybiological functions [37]. It is 
noted that S100A8/A9 can activate the vascular 
endothelium and increase endothelial permeability 
and has been found associated with atherogenesis 
and cardiovascular disease [37–39]. S100A8/A9 
complex plasma levels were significantly higher 
in patients with chronic heart failure [40]. It is 
suggested that serum S100A8/A9 was shown to 
be associated with the severity of CAD in patients 
with diabetes mellitus [41, 42]. Moreover, S100A8 
showing increased expression in patients with 
CAD [43]. In this study, it was also found that the 
up-regulated expression of S100A8 in CAD, which 
was in line with the previous reports. The present 
results further demonstrated the crucial role of 
S100A8 in CAD.
Among the top 10 up-regulated DEGs, matrix 
metallopeptidase 9 (MMP9) was also found to be 
related to CAD. It is reported that MMP9 is a gene 
that associated with atherosclerosis [44]. MMP9 is 
increased after vascular injury, particularly obvi-
ous in inflammatory atherosclerotic lesions [45]. 
Moreover, the concentration of MMP9 in plasma is 
a predictor of cardiovascular mortality [46]. Some 
studies have suggested that the plasma MMP9 is 
noticeably higher in CAD patients and higher circu-
lating level of MMP9 is related to an adverse prog-
nosis [47, 48]. In this study, increased expression 
of MMP9 was found, which is in line with previous 
reports. This further suggested the role of MMP9 
in the process of CAD. However, RT-qPCR result 
was inconsistent with the integrated analysis and 
the small sample may be related to this difference. 
Further research is required.
In this study, three down-regulated DEGs 
including PRKX, HSPH1 and ZMYND11 in CAD 
were foundwhich had not been reported in previous 
studies. Therefore, this result found new CAD-
-related genes and was facilitating the disclosure of 
the molecular mechanism underlying CAD. There 
are limitations to this study. Firstly, the blood 
samples and number of validated differentially ex-
pressed genes in the RT-qPCR were small. Larger 
numbers of blood samples and larger numbers of 
genes for validation are needed in further study. 
Secondly, the data in the GEO database were from 
leucocytes. And the identified DEGs can be con-
sidered as markers of CAD and were not linked to 
pathophysiological of CAD. Therefore, the expres-
sion of pathological genes in the atherosclerotic 
lesion  also needs testing in further research.
Conclusions
In summary, it was found that 7 DEGs in-
cluding IL1R2, ARRB2, PRKX, PLAUR, HSPH1, 
ZMYND11 and S100A8 may play essential roles in 
CAD. Additionally, the signaling pathway of MAPK 
may be a crucial biological signal in the pathology 
of CAD.
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